公开(公告)号：US20240158740A1

公开(公告)日：2024-05-16

申请号：US18281442

申请日：2022-03-08

Applicant: National University Corporation Tokyo Medical and Dental University ,  Takeda Pharmaceutical Company Limited

Inventor： Takanori TAKEBE ,  Norikazu SAIKI

IPC: C12N5/073 ,  C12N5/071

CPC classification number: C12N5/0605 ,  C12N5/069 ,  C12N2501/999 ,  C12N2506/45

Abstract: The present invention provides the following method as an approach for enriching desired cells, particularly, yolk sac mesoderm cells or amniotic ectoderm cells, contained in an embryogenesis region-specific micropattern structure of a cell cluster formed by differentiation-inducing factors from a colony of pluripotent stem cells such as iPS cells: a method for producing a cell cluster enriched in desired cells from pluripotent stem cells, comprising the step of two-dimensionally culturing the pluripotent stem cells under Wnt signal regulation. The present invention provides, for example, a method for producing a cell cluster enriched in yolk sac mesoderm cells from pluripotent stem cells, comprising the step of two-dimensionally culturing the pluripotent stem cells under conditions that activate Wnt signals, and a method for producing a cell cluster enriched in amniotic ectoderm cells from pluripotent stem cells, comprising the step of two-dimensionally culturing the pluripotent stem cells under conditions where Wnt signals have been suppressed.

公开(公告)号：US11969703B2

公开(公告)日：2024-04-30

申请号：US17476621

申请日：2021-09-16

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Robert Toso ,  Richard Spanggord ,  Mei Tan ,  Van Taiariol ,  Yekaterina Lin

IPC: B01J19/00 ,  B01D29/01 ,  B01F27/13 ,  B01F35/45 ,  B01F35/71 ,  B01J8/00 ,  B01J19/18

CPC classification number: B01J19/18 ,  B01D29/01 ,  B01F27/13 ,  B01F35/451 ,  B01F35/712 ,  B01J8/006 ,  B01J19/0066 ,  B01J2208/00805 ,  B01J2208/00858

Abstract: An antibody-resin coupling apparatus quickly and efficiently activates resin beads and couples them to antibodies, while preventing breakdown and crosslinking of the beads, thereby improving downstream column purification processes, extending the usable life of the resin beads, and increasing molecule capture efficiency of the resultant resin-antibody complexes, to allow improved isolation and purification of factor VIII molecules or other drug compounds.

公开(公告)号：US20240125767A1

公开(公告)日：2024-04-18

申请号：US17769452

申请日：2020-10-16

Applicant: Public University Corporation Yokohama City University ,  Takeda Pharmaceutical Company Limited

Inventor： Takanori TAKEBE ,  Norikazu SAIKI

IPC: G01N33/50 ,  C12N5/071 ,  C12N5/078

CPC classification number: G01N33/5014 ,  C12N5/0634 ,  C12N5/0697 ,  G01N33/5082 ,  C12N2503/04 ,  C12N2513/00 ,  G01N2500/10

Abstract: The present invention provides drug toxicity evaluation platforms (such as an evaluation method and a kit therefor) that enable detailed analysis of the possibility and the like of developing drug-induced damage (such as DILI) to the liver and other organs. The method for evaluating drug toxicity of the present invention includes: a step of adding a drug to a co-culture system of an organoid and blood cells; and a step of evaluating the toxicity of the drug to the organoid.

公开(公告)号：US20240124593A1

公开(公告)日：2024-04-18

申请号：US18347626

申请日：2023-07-06

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Daniel J. Sexton ,  Christopher TenHoor ,  Malini Viswanathan

IPC: C07K16/28 ,  A61K39/395 ,  A61K48/00 ,  A61K49/00 ,  G01N33/68

CPC classification number: C07K16/283 ,  A61K39/3955 ,  A61K48/00 ,  A61K49/0002 ,  G01N33/6854 ,  A61K2039/505

Abstract: The disclosure relates to antibodies that bind FcRn and methods of using these antibodies.

公开(公告)号：US11958845B2

公开(公告)日：2024-04-16

申请号：US17952546

申请日：2022-09-26

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masahiro Ito ,  Hideyuki Sugiyama ,  Takeshi Yamamoto ,  Keiko Kakegawa ,  Jinxing Li ,  Junsi Wang ,  Takahito Kasahara ,  Masato Yoshikawa

IPC: C07D413/14 ,  A61P25/28 ,  C07D413/10

CPC classification number: C07D413/14 ,  A61P25/28 ,  C07D413/10

Abstract: The present invention provides a heterocyclic compound having a HDAC6 inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound.
The present invention relates to a compound represented by the formula (I):




wherein each symbol is as defined in the description, or a salt thereof.

公开(公告)号：US11957867B2

公开(公告)日：2024-04-16

申请号：US16310916

申请日：2017-06-26

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Scott Richard Ariagno ,  Angela Teresa Muriset ,  Daniel Edward Roush ,  Denise A. Alexander ,  Madeleine Clare Gibson ,  Gin-Fu Chen

IPC: A61M5/00 ,  A61M5/31 ,  A61M5/315 ,  A61M25/02

CPC classification number: A61M5/008 ,  A61M5/3129 ,  A61M5/315 ,  A61M2005/3139 ,  A61M2025/024 ,  A61M2025/028 ,  A61M2205/586

Abstract: A syringe stabilizing apparatus has a base and a syringe support. The syringe support is vertically disposed above the base, elevating a fluid-filled portion of an infusion set vertically above the base and orienting a delivery end of the fluid-filled portion upwardly relative to a horizontal plane to take advantage of a gravitational effect on a fluid during delivery of the fluid from the fluid-filled portion to a patient. The syringe support comprises a first retainer and a selectively actuated tube clamp. The first retainer has an opening in which a rigid portion of the infusion set is received and retained therein without further user intervention. The selectively actuated tube clamp is operatively aligned with the first retainer. A flexible tube extending from the rigid portion of the infusion set extends through the selectively actuated tube clamp.

公开(公告)号：US20240117025A1

公开(公告)日：2024-04-11

申请号：US18507265

申请日：2023-11-13

Applicant: Takeda Pharmaceutical Company Limited

Inventor： William H. Frey, II ,  Leah Ranae Bresin Hanson ,  Sharon Pokropinski ,  Francisco M. Rausa, III

IPC: C07K16/18 ,  A61K9/00 ,  A61K31/401 ,  A61K31/4172 ,  C07K16/06

CPC classification number: C07K16/18 ,  A61K9/0043 ,  A61K31/401 ,  A61K31/4172 ,  C07K16/06 ,  A61K31/198

Abstract: The present invention provides, among other aspects, methods and compositions for treating a central nervous system (CNS) disorder by delivering a therapeutically effective amount of a composition of pooled human immunoglobulin G (IgG) to the brain via intranasal administration of the composition directly to the olfactory epithelium of the nasal cavity. In particular, methods and compositions for treating Alzheimer's disease are provided.

公开(公告)号：US20240109874A1

公开(公告)日：2024-04-04

申请号：US18504741

申请日：2023-11-08

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masami YAMADA ,  Shinkichi SUZUKI ,  Takahiro SUGIMOTO ,  Minoru NAKAMURA ,  Hiroki SAKAMOTO ,  Makoto KAMATA

IPC: C07D405/14 ,  A61K31/045 ,  A61K31/13 ,  A61K31/325 ,  A61K31/4035 ,  A61K31/4155 ,  A61K31/4406 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/55 ,  C07D209/46 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04

CPC classification number: C07D405/14 ,  A61K31/045 ,  A61K31/13 ,  A61K31/325 ,  A61K31/4035 ,  A61K31/4155 ,  A61K31/4406 ,  A61K31/4439 ,  A61K31/445 ,  A61K31/55 ,  C07D209/46 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D471/04

Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like.
The present invention relates to a compound represented by the formula (I) or a salt thereof.




wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US11938174B2

公开(公告)日：2024-03-26

申请号：US17018954

申请日：2020-09-11

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Colin Broom ,  Jeffrey Dayno

IPC: A61K38/55 ,  A61K35/16 ,  A61K38/57 ,  A61K45/06 ,  A61K39/395 ,  C07K16/18 ,  C07K16/28

CPC classification number: A61K38/57 ,  A61K35/16 ,  A61K38/55 ,  A61K45/06 ,  A61K39/3955 ,  C07K16/18 ,  C07K16/28 ,  A61K35/16 ,  A61K2300/00 ,  A61K39/3955 ,  A61K2300/00

Abstract: Compositions and methods useful for the treatment of neuromyelitis optica (NMO) or neuromyelitis optica spectrum disorder (NMOSD) are disclosed.

公开(公告)号：US20240091414A1

公开(公告)日：2024-03-21

申请号：US18355360

申请日：2023-07-19

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Venkata R. Garigapati ,  Tetsuya Matsuura

IPC: A61L27/52 ,  A61L27/16 ,  A61L27/18 ,  A61L27/26 ,  A61L27/38 ,  A61L27/54

CPC classification number: A61L27/52 ,  A61L27/16 ,  A61L27/18 ,  A61L27/26 ,  A61L27/3804 ,  A61L27/3834 ,  A61L27/54 ,  A61L2420/02

Abstract: The invention provides, inter cilia, ultra-thin conformal coated biological surfaces, such as living cells, cell clusters, tissues, organs, and hybrid synthetic organs, and methods of making the same, e.g., using click reactive water soluble polymers, under conditions that do not damage or significantly modify the biological surfaces. In some embodiments, the coated biological surfaces are suitable for delivery to a subject in need thereof.